BRAF V600E Status and Stimulated Thyroglobulin at Ablation Time Increase Prognostic Value of American Thyroid Association Classification Systems for Persistent Disease in Differentiated Thyroid Carcinoma

Table 1

Clinical and pathological differences between the BRAF^WT and BRAF^V600E groups.

	BRAF^WT (, 42.4%)	BRAF^V600E (, 57.6%)	value
Age (years)	51.5 ± 15.8	50.0 ± 15.4	0.261^A
years	167 (63.5%)	213 (59.7%)	0.359^B
Gender (F/M)	187/56	257/100	0.857^B
Incidentally	97 (36.9%)	59 (16.5%)	<0.001^B
Hashimoto’s thyroiditis	112 (42.9%)	140 (39.7%)	0.455^B
Tumour size (mean ± SD, cm)			0.003^A
cm	144 (45.4%)	173 (56.4%)	0.143^B
Multifocality	107 (40.7%)	197 (55.2%)	<0.001^B
Histology
Classic	85 (25.2%)	252 (74.8%)	<0.001^C
FVPTC	110 (69.2%)	49 (30.8%)
Tall cell	5 (14.7%)	29 (85.3%)
T (T3-T4)	78/270 (28.8%)	192/270 (71.2%)	<0.001^D
N1 (a+b)	56/181 (30.9%)	125/181 (69%)	<0.001^D
Distant metastases	15 (5.7%)	7 (2%)	0.015^B
R1-2	63/194 (32.4%)	131/194 (67.5%)	<0.001^D
Extrathyroidal extension	78 (28.9%)	192 (71.1%)	<0.001^B
Vascular invasion	49/104 (47.1%)	55/104 (52.9%)	0.328^B
Stage (III-IV)	48/170 (28.2%)	122/170 (71.7%)	0.039^D
Number of patients who underwent I131 treatment	219 (83.3%)	336 (94.4%)	<0.001^B
mCi ablation
30 mCi	34 (55.7%)	27 (44.3%)	0.001^D
50 mCi	41 (47.1%)	46 (57.9%)
100 mCi	144 (35.4%)	263 (64.6%)
WBS postdose (metastatic uptake)	20 (9.3%)	19 (5.7%)	0.126^B
ng/ml	58 (42.3%)	79 (57.7%)	0.421^B
ATA risk
Low	123 (58.3%)	88 (41.7%)	<0.001^D
Intermediate	123 (32.5%)	255 (67.5%)
High	17 (54.8%)	14 (45.2%)
Years follow-up			0.629
Recurrence	4 (1.6%)	16 (4.6%)	0.040^B
Positive DRS	41 (15.6%)	87 (24.4%)	0.009^B
Persistent disease	33 (12.5%)	82 (23%)	0.001^B

^A-test; ^BFisher’s exact test; ^Cchi-square test; ^Dlinear-by-linear association test.